AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06540261
Drug: Levofolinate
RxNorm normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06540261
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06540261
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06504992
Drug: Vancomycin 1000 MG
RxNorm normalized name: vancomycin 1000 MG
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
Trial: NCT05199337
Drug: ZN-d5
RxNorm normalized name: VITAMIN D5
DrugBank: 1alpha-Hydroxyvitamin D5 (DB13097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-d5 will be administered orally
Trial: NCT04971746
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Days 1 and 13, participants will receive an oral dose of pirfenidone.
Trial: NCT04971746
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Days 1 and 13, participants will receive an oral dose of nintedanib.
Trial: NCT04854174
Drug: ZN-d5
RxNorm normalized name: VITAMIN D5
DrugBank: 1alpha-Hydroxyvitamin D5 (DB13097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agent; 25 mg formulation
Trial: NCT05636228
Drug: INV-102
RxNorm normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INV-102 Ophthalmic Solution
Trial: NCT06478186
Drug: triamcinolone acetonide extended-release injectable suspension; TCA-ER
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
Trial: NCT06478186
Drug: Triamcinolone Acetonide- Immediate Release;TCA-IR
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
Trial: NCT04977453
Drug: GI-101
RxNorm normalized name: GI-101
DrugBank: GI-101 (DB17243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Trial: NCT04977453
Drug: Pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
Trial: NCT04977453
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be administered at an approved dose orally.
Trial: NCT04977453
Drug: GI-101A
RxNorm normalized name: camphor
DrugBank: GI-101 (DB17243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Trial: NCT06537700
Drug: OnabotulinumtoxinA OBT-A
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
Trial: NCT05546879
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
Trial: NCT05546879
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Trial: NCT05546879
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
Trial: NCT05846659
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
Trial: NCT05283161
Drug: cannabidiol and tetrahydrocannabinol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
Trial: NCT05411705
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
Trial: NCT05411705
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-rhTPO treatment
Trial: NCT06595017
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
Trial: NCT06595017
Drug: Lidocaine (drug)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
Trial: NCT06595017
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
Trial: NCT06593717
Drug: Fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
Trial: NCT05710848
Drug: STM-416
RxNorm normalized name: STM 217
DrugBank: STM-217 (DB17358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STM-416 monotherapy
Trial: NCT06589817
Drug: Hydrochloride Carliprazine capsules
RxNorm normalized name: cariprazine hydrochloride
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Trial: NCT06589817
Drug: Aripiprazole tablets
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Trial: NCT04725864
Drug: Progesterone vaginal tablet
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
Trial: NCT00002021
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05946837
Drug: Indocyanine green (ICG) dye
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
Trial: NCT06601036
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo fiberoptic intubation under sevoflurane sedation.
Trial: NCT04049539
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05777031
Drug: Collagenase Clostridium Histolyticum (CCH)
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
Trial: NCT06515834
Drug: FE 999301
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
Trial: NCT05602818
Drug: Soticlestat 300 mg
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05602818
Drug: Soticlestat 600 mg
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05602818
Drug: Soticlestat 900 mg
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05602818
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06603142
Drug: Febuxostat 20MG Tablets
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 20MG Tablets
Trial: NCT06603142
Drug: Febuxostat 20MG Placebo
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 20MG Placebo
Trial: NCT06603142
Drug: Febuxostat 40MG Tablets
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 40MG Tablets
Trial: NCT06603142
Drug: Febuxostat 40MG Placebo
RxNorm normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 40MG Placebo
Trial: NCT05006352
Drug: DNL343
RxNorm normalized name: DNL343
DrugBank: DNL343 (DB18678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT06590662
Drug: Solriamfetol
RxNorm normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period.
Trial: NCT06601309
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
Trial: NCT06601309
Drug: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
Trial: NCT06601309
Drug: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
Trial: NCT05766410
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4, 6 inhibitor
Trial: NCT05766410
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK4, 6 inhibitor
Trial: NCT05766410
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4, 6 inhibitor
Trial: NCT05766410
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine therapy
Trial: NCT06212973
Drug: Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln
RxNorm normalized name: epinastine
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
Trial: NCT06212973
Drug: Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
RxNorm normalized name: epinastine
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
Trial: NCT05087706
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400mg qd po
Trial: NCT05087706
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide was administered orally at a daily dose of 50 mg
Trial: NCT05087706
Drug: Leuprorelin
RxNorm normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
Trial: NCT05102734
Drug: Nitroglycerin Topical Product
RxNorm normalized name: nitroglycerin Topical Product
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin solution
Trial: NCT06310876
Drug: ABBV-CLS-7262
RxNorm normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • single oral Dose 1
Trial: NCT06310876
Drug: ABBV-CLS-7262
RxNorm normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • single oral Dose 2
Trial: NCT06310876
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • single oral dose
Trial: NCT04794530
Drug: cocoa flavanols
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
Trial: NCT05661643
Drug: Temozolomide capsule
RxNorm normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
Trial: NCT04596267
Drug: Pitolisant
RxNorm normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8.9mg Pitolisant for 5 days
Trial: NCT06493864
Drug: BL-B16D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05005182
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04895423
Drug: Cyclosporine therapy
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine per os 3 mg/m2 2 times a day within 12 months
Trial: NCT04895423
Drug: Dupilumab therapy
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
Trial: NCT05926804
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days of Lansoprazole (30 mg BID) (days 1-14)
Trial: NCT05926804
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of Amoxicillin (1000 mg BID) (days 1-7)
Trial: NCT05926804
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of Metronidazole (500 mg BID) (days 8-14)
Trial: NCT05356897
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06205875
Drug: PCIA with morphine
RxNorm normalized name: opium alkaloids with morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
Trial: NCT05328102
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug
Trial: NCT03125486
Drug: SC belimumab 200 mg
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
Trial: NCT06481306
Drug: BMS-986470
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06060626
Drug: Sedation using only Propofol.
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in whom only propofol will be administered during sedation.
Trial: NCT04911361
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
Trial: NCT04232358
Drug: Local anesthesia injections
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
Trial: NCT00253149
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05163522
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered